相关实验视频
Updated: Jun 7, 2025
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
429
阿尔茨海默病:第二部分 - - 现在的情况
1Universidade de São Paulo, Faculdade de Medicina, São Paulo SP, Brazil.
Arquivos de neuro-psiquiatria
|November 12, 2024
概括
最近阿尔茨海默病 (AD) 的进展包括更容易诊断的血生物标志物和新的抗粉样蛋白单克隆抗体. 虽然这些进展显示出温和的临床效应,但为未来的研究和改善AD管理提供了希望.
科学领域:
- 神经学 神经学
- 生物标志物研究 生物标志物研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 自2011年以来,阿尔茨海默氏病 (AD) 的诊断和治疗发生了显著的进化.
- 最近的发现,特别是生物标志物的发现,正在改变阿尔茨海默病的诊断.
- 已建立的诊断标准已经更新,反映了新的科学理解.
研究的目的:
- 从临床神经病学家的角度回顾阿尔茨海默病诊断和治疗的现状.
- 讨论新生物标志物和单克隆抗体对AD治疗的影响.
- 解决新诊断标准和新兴疗法的影响.
主要方法:
- 对阿尔茨海默病的临床经验和最新科学文献的审查.
- 分析新诊断标准和生物标志物 (包括基于血的) 对AD诊断的影响.
- 对新批准的抗粉样蛋白单克隆抗体的疗效和作用的评估.
主要成果:
- 基于等离子体的生物标志物正在出现,准备彻底改变生物AD诊断,尽管需要公众教育.
- 三种针对β-粉样蛋白的单克隆抗体已获得批准;两种显示具有统计学意义的,尽管小,临床益处.
- 这些抗体有效地减少大脑粉样蛋白质斑块 (通过PET) 并改变脑脊液生物标志物 (Aβ42,p-tau) 而不是改善神经心理或功能结果.
结论:
- 新兴的血生物标志物将简化AD诊断和对其病理生理学的监测.
- 目前抗粉样蛋白抗体的适度临床益处对未来的研究和药物开发是令人鼓舞的.
- 针对阿尔茨海默症提出了新的诊断标准,引发了关于其临床应用的辩论.
更多相关视频
11:01Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
13.6K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:30Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
01:15Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482
01:13Amnesia
102
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
102
01:24Parkinson's Disease: Treatment
222
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
222